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Abstract
Synucleins belong to a family of intrinsically unstructured proteins that includes alpha-synuclein (aSyn), beta-synuclein (bSyn)
and gamma-synuclein (gSyn). aSyn is the most studied member of the synuclein family due to its central role in genetic and
sporadic forms of Parkinson’s disease and other neurodegenerative disorders known as synucleionopathies. In contrast,
bSyn and gSyn have been less studied, but recent reports also suggest that, unexpectedly, these proteins may also cause
neurotoxicity. Here, we explored the yeast toolbox to investigate the cellular effects of bSyn and gSyn. We found that bSyn is
toxic and forms cytosolic inclusions that are similar to those formed by aSyn. Moreover, we found that bSyn shares similar
toxicity mechanisms with aSyn, including vesicular trafficking impairment and induction of oxidative stress. We demonstrate
that co-expression of aSyn and bSyn exacerbates cytotoxicity, due to increased dosage of toxic synuclein forms, and that they
are able to form heterodimers in both yeast and in human cells. In contrast, gSyn is not toxic and does not form inclusions in
yeast cells. Altogether, our findings shed light into the question of whether bSyn can exert toxic effects and confirms the
occurrence of aSyn/bSyn heterodimers, opening novel perspectives for the development of novel strategies for therapeutic
intervention in synucleinopathies.
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Introduction
The synuclein family consists of three intrinsically unstructured
proteins: alpha-synuclein (aSyn) and beta-synuclein (bSyn),
which arewidely expressed in the central nervous system includ-
ing neocortex, hippocampus, striatum, thalamus and cerebel-
lum, and gamma-synuclein (gSyn), which is predominantly
expressed in the peripheral nervous system (1).
The precise function of these three vertebrate-specific pro-
teins is unclear. Triple knockout mice exhibit a mild phenotype
with alterations in synaptic structure and transmission, age-
dependent neuronal dysfunction, as well as reduced survival
(2). Recently, synucleins were reported to play a role in the early
steps of synaptic vesicle endocytosis, showing some degree of
functional redundancy (3). The three proteins share a highly
conserved N-terminal domain and a less-conserved C-terminal
region (4). Human aSyn is 140 amino acids while bSyn is 134
amino acids long. The two proteins share 61% sequence hom-
ology. gSyn is 127 amino acids long and shares 55.9 and 54.3%
sequence homology with aSyn and bSyn, respectively (1,5). The
region of highest homology between the three synuclein proteins
is the N-terminal region.
aSyn is the most studied member of the family due to its gen-
etic association with familial and sporadic forms of Parkinson’s
disease (PD). aSyn is also the major component of protein inclu-
sions known as Lewy bodies (LBs) or Lewy neurites (LNs), typical
pathological hallmark inclusions in PD and other neurodegen-
erative disorders known as synucleinopathies (6).
bSyn and gSyn do not seem to be present in LBs (7), and have
not been strongly linked to synucleinopathies. However, a recent
study revealed bSyn can also induce dopaminergic cell loss when
expressed in rat brain (8), challenging initial reports suggesting it
could act as a scavenger of aSyn aggregation andneurotoxicity, in
several in vivo and in vitro models (9–12).
bSyn was thought to be less prone to aggregation than aSyn
since it lacks part of the non-β-amyloid component (NAC) region,
known to be important for aggregation. However, in particular
conditions such as exposure to metal ions, macromolecular
crowding and pesticides, aggregation and fibrillation of bSyn
can be induced (13). Moreover, V70M and P123H mutations in
bSyn were associated with rare cases of dementia with LBs
(DLBs) (14). When overexpressed in a neuroblastoma cell line,
these mutations induced the formation of lysosomal inclusions,
an effect that was enhanced by co-expression with aSyn (15).
Also, overexpression of aSyn exacerbated the progressive neuro-
degeneration of transgenic mice expressing P123H bSyn (16).
Stronger evidence of a neuropathological role of bSynwas recent-
ly described in a study where wild-type (WT) human bSyn was
found to be neurotoxic in primary neuronal cultures and when
expressed in the rat substantia nigra (8).
gSyn was associated with tumor progression and metastasis
in a wide variety of cancers such as breast cancer, ovarian and
brain tumors (17,18), and alsowith neurodegenerative and ocular
diseases (19). Abnormal structures positive for gSyn were re-
ported in brains of some patients with PD, DLB and Hallervor-
den–Spatz syndrome (20,21). More recently, gSyn-positive
inclusions were found in the cell bodies and/or in the axonal
compartment of the affected motor neurons of 30% of amyo-
trophic lateral sclerosis (ALS) patients (22).
Several posttranslational modifications (PTMs) of aSyn were
found to modulate neurotoxicity, such as phosphorylation,
oxidation and nitration (23–26). Among them, phosphorylation
is the most studied, as 90% of the aSyn aggregated in LBs was
found to be phosphorylated on serine 129 (S129) (27,28).
Additional phosphorylation sites in aSyn have been identified
and studied [Y39, S87, Y125, Y133 and Y136 (29)]. However, al-
though distinct aSyn phosphorylation patterns were observed
in synucleinopathies (30,31), the precise effect of phosphoryl-
ation on aSyn aggregation and toxicity is still unclear.
PTMs in bSyn and gSyn are less studied than those in aSyn.
bSyn was originally described as a phosphoprotein that under-
goes phosphorylation both in vitro and in vivo (32). Although the
human Polo-like kinases (PLKs) 2 and 3 were found to phosphor-
ylate bSyn at serine 118 (S118), it is still unclear whether this
modification plays a role in pathology (5).
Saccharomyces cerevisiae has been widely used to study the
basic molecular mechanisms underlying various neurodegen-
erative diseases (33). Here, we used yeast as an unbiased living
test tube to interrogate the intrinsic cytotoxicity of the three sy-
nuclein family members, and to dissect the molecular mechan-
isms of toxicity. We found that, like aSyn, bSyn is toxic and
forms inclusions. In contrast, gSyn is not toxic and does not
form inclusions. We found that the cellular pathways affected
by bSyn are similar to those affected by aSyn, including impair-
ment of vesicular trafficking and induction of oxidative stress.
Interestingly, we demonstrate that co-expression of aSyn and
bSyn exacerbates cytotoxicity, due to increased gene dosage,
and that these two synucleins form heterodimers in both yeast
and in human human embryonic kidney (HEK) cells.
Altogether, our study provides novel insight into the molecu-
lar effects of the three synuclein family members, establishing
the basis for future studies that may impact on our understand-
ing of synucleinopathies.
Results
bSyn is toxic and forms inclusions when expressed
in yeast cells
In order to evaluate whether human bSyn and gSyn affected
yeast cell growth, we expressed these proteins, fused with GFP,
in multi-copy plasmids using a galactose-inducible promoter
(GAL1) (Table 1). Growth was assessed using a spotting assay
and compared with the strain containing the empty vector as a
control (Fig. 1A). As described before (35), expression of aSyn in
yeast cells is toxic and results in reduced cell growth (Fig. 1A).
However, cells expressing bSyn also displayed reduced growth
compared with control cells, suggesting that the expression of
this synuclein is also toxic (Fig. 1A). Cells expressing gSyn pre-
sented similar growth to the control cells, indicating that this sy-
nuclein is not toxic in yeast (Fig. 1A). To investigate whether the
growth defect was due to cytotoxicity, these results were further
confirmed by propidium iodide (PI) staining and flow cytometry
analysis of cells where plasmamembrane integrity was compro-
mised (Fig. 1B). In fact, 6 h after induction of expression, 20.4 ± 1%
of the yeast cells expressing aSyn-GFP and 16.3 ± 1.4% of the yeast
cells expressing bSyn-GFP were PI positive, compared with only
4.3 ± 1.4% of cells containing the empty vector, or 7.8 ± 3.0% of
cells expressing gSyn (non-significant) (Fig. 1B).
We next assessed the correlation between cytotoxicity and the
subcellular distribution of synuclein proteins. Cells expressing
aSyn, bSyn or gSyn fused to GFP were analyzed by fluorescence
microscopy, and the percentage of cells displaying inclusions
was counted (Fig. 1C). As reported before, aSyn expression in
yeast leads to the formation of cytoplasmic inclusions (35). In
our experimental conditions, we found 42 ± 6.1% of the cells dis-
played aSyn inclusions. Interestingly, cells expressing bSyn-GFP
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also presented cytoplasmic inclusions (22.4 ± 4.2%). In contrast, no
inclusions were visible in the cells expressing gSyn-GFP. As with
aSyn, both bSyn-GFP and gSyn-GFP were present at the plasma
membrane and in the cytosol (Fig. 1C). We next asked whether
the differences in toxicity and inclusion formationwere due to dif-
ferent expression levels of the different synuclein homologs.
Using immunoblot analyses, we found bSyn-GFP and gSyn-GFP
were expressed at similar levels with aSyn-GFP (Fig. 1D).
Given that only bSyn formed inclusions and induced cytotox-
icity,we focused the studyon this synuclein. To evaluate if the in-
clusions formed by aSyn-GFP or bSyn-GFP have similar dynamic
properties, we used fluorescence recovery after photobleaching
(FRAP), an assay we have previously employed for characterizing
aSyn inclusions (36). Interestingly, we found that inclusions
formed by aSyn-GFP and bSyn-GFP present similar FRAP recovery
profiles, demonstrating these inclusions display comparable
protein immobile fractions and mean residence time (Fig. 1E).
aSyn expression in yeast cells induces oxidative stress by
increasing reactive oxygen species (ROS) production (37), and by
affecting mitochondria function (38). Thus, we compared the
intracellular levels of superoxide radical in cells expressing
aSyn or bSyn using dihydroethidium (DHE) and flow cytometry
(Fig. 1F). As expected, the expression of aSyn in yeast cells leads
to the increase of superoxide radical levels (39).We observed that
the expression of bSyn in yeast cells also results in a significant
increase in the levels of superoxide radical (Fig. 1F).
Altogether, these results demonstrate that bSyn expression in
yeast cells is toxic and forms inclusions that are similar to those
formed by aSyn. In contrast, gSyn is not toxic and does not form
inclusions at the levels of expression tested.
bSyn promotes endoplasmic reticulum-to-Golgi
trafficking defects in yeast
Several studies showed that aSyn disrupts multiple intracellular
trafficking pathways, such as endoplasmic reticulum (ER)-to-
Golgi trafficking (40). Interestingly, genes that promote ER-to-
Golgi trafficking rescue aSyn toxicity, while genes that negatively
regulate ER-to-Golgi trafficking enhance aSyn toxicity (40). To
evaluate if bSyn toxicity is also associated with ER-to-Golgi traf-
ficking impairment, we tested the effects of previously described
suppressors (Ypt1, Ykt6 and Ubp3) and enhancers (Gyp8 and
Pmr1) of aSyn toxicity on bSyn toxicity (36,40). Both types of gen-
eticmodifiers were co-expressedwith aSyn-GFP or bSyn-GFP and
the effect on toxicity and inclusion formation was evaluated 6 h
after expression induction (Fig. 2). Although the co-expression of
Ypt1, Ykt6 and Ubp3 significantly reduced the toxicity of aSyn
and bSyn (Fig. 2A), no significant differences in inclusion forma-
tionwere observed (Fig. 2B). In contrast, co-expression of Gyp8 or,
to a lesser extent, Pmr1, significantly increased toxicity and
inclusions formation of aSyn and bSyn (Fig. 2B).
We also evaluated if the enhancers of aSyn and bSyn toxicity
(Gyp8 and Pmr1) could enhance gSyn toxicity, but found no effect
(SupplementaryMaterial, Fig. S1A).Moreover, neither genemodi-
fied gSyn-GFP inclusion formation (Supplementary Material,
Fig. S1B).
To exclude that the phenotypes observed resulted from an
effect of the modifiers on the expression levels of the synuclein
proteins, we preformed western blot analyses. We found that
total aSyn, bSyn and gSyn levels were not significantly affected
by the co-expression of the geneticmodifiers (Fig. 2C and Supple-
mentary Material, Fig. S1C).
Altogether, these results indicate that bSyn is also associated
with ER-to-Golgi trafficking defects. In contrast, gSyn is not toxic
even when vesicle trafficking defects are genetically induced.
V70m and P123H bSyn mutations increase inclusion
formation without affecting toxicity
Sporadic and familial cases of DLBs were previously associated
with the point mutations V70M and P123H in bSyn, respectively
(14). Here, we analyzed the effect of these mutations on bSyn
toxicity and inclusion formation yeast (Fig. 3). Interestingly,
while V70M and P123H mutations had no effect on bSyn toxicity
(Fig. 3A), the percentage of cells with inclusionswas 2-fold higher
(∼40%) that that of cells expressing WT bSyn (∼20%) (Fig. 3B).
Wenext evaluated the effect of V70Mand P123Hmutations on
the levels of expression of bSyn-GFP. Using immunoblot ana-
lyses, we observed all three variants of bSyn were expressed at
similar levels after 6 h of expression induction (Fig. 3C).
The phospho-mimic mutation S118D increases bSyn
toxicity and inclusion formation
bSyn is phosphorylated by PLK2 and 3 on serine 118 (S118) (5).
However, it is not known if this PTM has a pathological role.
Thus, we addressed this question using mutants that either
mimic (S118D) or block phosphorylation (S118A or S118G). Cells
expressing the S118D mutant exhibited a more severe growth
defect phenotype, while cells expressing the S118A or S118G mu-
tants behaved as those expressingWT bSyn (Fig. 4A). We then as-
sessed the correlation between cytotoxicity and the subcellular
distribution of S118D, S118A and S118G aSyn-GFP, by fluorescence
microscopy.Whilewe found no different in the percentage of cells
displaying inclusions between the different variants of bSyn (data
not shown), we found that cells expressing the phospho-mimic
S118D mutation presented a significant increase in the number
of inclusions per cell (Fig. 4B). We next assessed whether the dif-
ferences in toxicity and inclusion formation were due to different
expression levels of the variants of bSyn-GFP. Using immunoblot
analyses, we observed that all variants were expressed at similar
levels after 6 h of expression induction (Fig. 4C).
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Figure 1. bSyn is toxic and forms inclusions in yeast cells. (A) Cytotoxicity of aSyn, bSyn and gSyn in yeast cells compared with the empty vector, assessed by spotting
assay. Photos were taken 4 days after incubation at 30°C (B) Frequency of PI positive cells assessed by flow cytometry, after 6 h of induction of expression of the different
synuclein proteins. (C) Fluorescencemicroscopy visualization (left panel) and percentage of cells with aSyn or bSyn inclusions (right panel). (D) Expression levels of aSyn,
bSyn and gSyn-GFP in yeast cells assessed by western blot analysis of total protein extracts (left panel). Densitometric analysis of the immunodetection of GFP relative to
the intensity obtained for PGK used as loading control presented in arbitrary units (a.u.) (right panel). (E) FRAP recovery curves for aSyn and bSyn-GFP inclusions on yeast
cells. For each strain, at least six inclusions in different cells were analyzed. Each plot represents mean ± SD for each time point for all FRAP experiments. (F) Superoxide
radical levels in yeast cells expressing either aSyn or bSyn after 24 h of expression induction, assessed by flow-cytometry using theDHE probe. Results shown are fromone
representative experiment from at least three independent experiments. Values represent the mean ± SD of at least three independent measurements (***P < 0.001,
**P < 0.01, *P < 0.05).
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Overall, these results indicate that phosphorylation of bSyn at
S118 might contribute to toxicity and inclusions formation in
yeast cells.
Co-expression of aSyn and bSyn increases toxicity
and inclusion formation
Next, we asked whether aSyn and bSyn altered each other’s
behavior in yeast cells. Upon co-expression of both proteins, we
found that this resulted in a strong increase in toxicity, with com-
plete lack of growth (Fig. 5A). To clarify if this phenotypewas due
to a synergistic or an additive effect, we used the same conditions
and co-expressed aSyn plus aSyn and bSyn plus bSyn, using ex-
pression vectors with different auxotrophic markers. We found
that co-expression of aSyn plus aSyn and bSyn plus bSyn also in-
creased toxicity (Fig. 5A). Next, we evaluated cells where plasma
membrane integrity was compromised using PI staining and flow
cytometry analysis, 12 h after induction of expression (Fig. 5B).
No significant differences were observed in the percentage of
PI-positive cells when aSyn plus bSyn, aSyn plus aSyn or bSyn
plus bSyn were co-expressed (Fig. 5B). Regarding the percentage
of cells with inclusions, a slight but significant increase was
observed when aSyn was co-expressed with bSyn, compared
with aSyn plus aSyn or bSyn plus bSyn expressing cells, 6 h
after expression induction (Fig. 5C).
In parallel, we also evaluated the effect of the co-expression
of gSyn with aSyn and bSyn. We observed that co-expression of
gSyn-GFP with aSyn-GFP or bSyn-GFP reduced the toxicity of
both proteins, as assessed by spotting assay and by PI staining
(Fig. 5A and B). Moreover, gSyn-GFP co-expression with aSyn-GFP
or bSyn-GFP also reduced the percentage of cells with inclusions
(Fig. 5C).
Next, we assessedwhether the phenotypes observedwere due
to altered expression levels of the different synuclein proteins,
Figure 2. Vesicular trafficking genes as modifiers of bSyn toxicity. (A) Spotting assay of the indicated yeast cells. Photos were taken 3 days after incubation at 30°C
(B) Intracellular localization of aSyn and bSyn-GFP (upper panel) and percentage of yeast cells containing inclusions (lower panel) in the indicated yeast strains,
assessed by fluorescence microscopy after 6 h of expression induction. Values represent the mean ± SD (***P < 0.001 versus WT; ### < 0.001 versus aSyn). (C) aSyn, bSyn
and gSyn-GFP expression levels in the indicated yeast strains assessed by western blot analysis of total protein. A representative result is shown from at least three
independent experiments.
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using immunoblot analyses (Fig. 5D).We observed that in the con-
ditions tested, using multicopy expression vectors, the co-expres-
sion of synuclein proteins affected protein levels (Fig. 5D). Thus,
this might contribute to an alleviation of the phenotypes ob-
served. In particular, we observed that co-expression of aSyn or
bSynwith gSyn-GFP resulted in reduced protein levels, accounting
for the reduced toxicity and inclusion formation (Fig. 5D).
We then assessed whether aSyn, bSyn and gSyn were able to
form heterodimers in yeast cells, taking advantage of the bimol-
ecular fluorescence complementation assay (BiFC) (41). In this
approach, aSyn, bSyn and gSyn were tagged with the N-terminal
half of Venus (VN) or the C-terminal half of Venus (VC), respect-
ively. In the BiFC assay, the occurrence of Venus fluorescence sig-
nal indicates the formation of at least dimeric species. As
expected, we observed the formation of aSyn and bSyn dimers/
oligomers (Fig. 6A). Interestingly, we not only observed the for-
mation of aSyn/bSyn heterodimers, but also the formation of in-
clusions composed of both aSyn and bSyn (Fig. 6A). The intensity
of the fluorescence signal was further evaluated by flow cytome-
try, revealing that the pair VN-aSyn/bSyn-VC is more competent
in forming heterodimers/oligomers than the pair VN-bSyn/aSyn-
VC (Fig. 6B). In addition, the cells expressing the pair VN-aSyn/
bSyn-VC displayed lower mean fluorescence intensity (MFI)
when compared with the pair VN-aSyn/aSyn-VC, but higher
than the pair VN-bSyn/bSyn-VC, indicating an additive effect
on the formation of heterodimers/oligomers when aSyn and
bSyn were co-expressed (Fig. 6C).
We also evaluated the ability of gSyn to form heterodimers
with aSyn and bSyn in yeast cells. We observed heterodimer for-
mation just for one combination: VN-aSyn + gSyn-VC. Interest-
ingly, the signal was only detected at the plasma membrane
and we observed no inclusion formation. In all other combina-
tions we found no fluorescent signal, suggesting the orientation
of the proteins in the heterodimers does not enable the reconsti-
tution of the functional fluorophore (Fig. 6 and Supplementary
Material, Fig. S2).
Importantly, the differences observed when aSyn and bSyn
were co-expressed were not due to different expression levels
of the corresponding fusion proteins, as no significant differ-
ences were detected by immunoblot analysis (Fig. 6D).
aSyn and bSyn form heterodimers in both yeast
and mammalian cell models
The formation of heterodimers between aSyn and bSyn had not
been previously reported. Therefore, to confirm the data obtained
Figure 3.The effect of V70Mand P123Hmutations onbSyn inclusion formation and toxicity. (A) CytotoxicityofWT, V70Mor P123HbSyn expression in yeast cells compared
with the empty vector assessed by spotting assay. Photoswere taken 3 days after incubation at 30°C. (B) Fluorescencemicroscopy visualization (left panel) and percentage
of cells with bSyn inclusions (right panel) after 6 h of expression induction. (C) Expression levels of aSyn, WT, V70M or P123H bSyn-GFP in yeast cells assessed by western
blot analysis of total protein extracts. A representative result is shown from at least three independent experiments. Values represent the mean ± SD (**P < 0.01).
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in yeast, we performed the BiFC assay in HEK cells (HEK293).
Cells were co-transfected with different combinations of the
constructs encoding aSyn or bSyn fused to the N- or C-terminal
fragments of Venus. We observed that both combinations of
aSyn/bSyn constructs resulted in the formation of heterodimers,
as observed in yeast cells (Fig. 7A).
Immunoblot analyses confirmed the expression of the
various BiFC constructs was identical (Fig. 7B).
In order to confirm that untagged aSyn and bSyn behaved
similarly to the BiFC constructs, we performed inmmunocyto-
chemistry in cells transfected with aSyn, bSyn-V5, or aSyn +
bSyn-V5. In cells co-expressing both proteins, the subcellular dis-
tribution pattern was identical, in agreement with the findings
using the BiFC assay (Fig. 7C).
Altogether, we confirmed that aSyn and bSyn can form het-
erodimers in human cells, further supporting a possible additive
effect toward pathology.
Monomeric aSyn and bSyn do not interact in solution
To evaluate if aSyn and bSyn heterodimer formation occurred
during the aggregation process or was already initiated between
the two monomeric proteins in solution, we performed nuclear
magnetic resonance (NMR) spectroscopy. NMR spectroscopy is
able to detect and quantify both strong and weak molecular in-
teractions and provides residue resolution about the interaction.
To this end, we labeled bSynwith 15N and recorded a two-dimen-
sional {1H–15N}-HSQCexperiment, which provides afingerprint of
the backbone resonances of bSyn (Fig. 8A). Next, we tagged aSyn
with the nitroxide-label S-(1-oxyl-2,2,5,5-tetramethyl-2,5-dihy-
dro-1H-pyrrol-3-yl)methyl methanesulfonothioate (MTSL) at
position 90, in order to increase the sensitivity of detection to-
ward intermolecular interactions (42). In particular, because
bSyn does not carry a paramagnetic center, any NMR signal
broadening that would be observed upon addition of aSyn
Figure 4. The effect of S118 phosphorylation on bSyn inclusion formation and toxicity. (A) Cytotoxicity of WT, S118D, S118A or S118G bSyn expression in yeast cells
compared with the empty vector assessed by spotting assay. Photos were taken 3 days after incubation at 30°C. (B) Fluorescence microscopy visualization (left panel)
and percentage of cells with bSyn inclusions (right panel) after 6 h of expression induction. The percentage of cells with <5 and with ≥5 inclusions per cell is
represented (right panel). (C) Expression levels of WT, S118D, S118A or S118G bSyn-GFP in yeast cells assessed by western blot analysis of total protein extracts.
A representative result is shown from at least three independent experiments. Values represent the mean ± SD (***P < 0.001, **P < 0.01).
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Figure 5. Co-expression of aSyn, bSyn and gSyn toxicity and inclusion formation in yeast cells. Co-expression of the different synuclein proteins was achieved using
expression vectors with different auxotrophic markers. (A) Cytotoxicity of aSyn-GFP and bSyn-GFP, either alone or co-expressed in yeast cells compared with the
empty vector and assessed by spotting assay. Pictures were taken 4 days after incubation at 30°C. (B) Frequency of PI positive cells assessed by flow cytometry, after
12 h of induction of expression of the different synuclein proteins in the indicated combinations. (C) Fluorescence microscopy visualization (left panel) and
percentage of cells with inclusions expressing the indicated synuclein proteins (right panel), after 6 h of expression induction. (D) Expression levels of aSyn, bSyn and
gSyn-GFP in the indicated yeast strains after 12 h of expression induction, assessed by western blot analysis of total protein extracts. A representative result is shown
from at least three independent experiments. Values represent the mean ± SD (***P < 0.001, **P < 0.01 and *P < 0.05).
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Figure 6. aSyn and bSyn form homo- and hetero-dimers/oligomers in yeast. Yeast cells were transformed with BiFC constructs encoding aSyn, bSyn or gSyn tagged with
N-terminal half of Venus (VN) or C-terminal half of Venus (VC) under the control of GAL1 inducible promoter. aSyn-GFP, bSyn-GFP and VN-aSyn + VC were used as
controls. (A) Fluorescence microscopy after 6 h induction of synuclein expression, showing fluorescence complementation signal in living cells. Scale bar: 5 μm.
(B) GFP intensity versus counts assessed by flow cytometry 6 h after synuclein expression induction. At least 100 000 cells were measured per strain and experiment.
Results shown are from one representative experiment from three independent experiments. Control: transformation of yeast cells with VN-aSyn + VC; VN-bSyn + VC
or VN-gSyn + VC does not result in positive fluorescence intensity, indicating that fluorescence is caused only by specific protein interactions. (C) Mean fluorescence
intensity for the indicated plasmid combinations. The results are mean from three independent experiments ± SD. Significance of differences was calculated with
one-way ANOVA with Bonferroni’s multiple comparison test (****P < 0.0001; #P < 0.05; ###P < 0.001; ####P < 0.0001 versus control). (D) Immunoblotting analysis of total
protein extracts 6 h after induction of synuclein expression of transformants, used in the BiFC experiments.
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Figure 7. aSyn and bSyn form heterodimers in HEK293 cells. HEK293 cells were transfected with BiFC constructs encoding either aSyn or bSyn taggedwith the N-terminal
(VN) or C-terminal half of Venus (VC) under the control of the CMV promoter. (A) Fluorescence microscopy pictures 48 h after transfection. Scale bar: 50 μm.
(B) Representative immunoblot to evaluate the levels of expression of the various constructs in HEK293 cells, showing aSyn and bSyn fused-to the VN- or VC-part,
detected by using a pan-specific synuclein specific antibody, and the loading control. (C) Fluorescence microscopy of cells transfected with untagged aSyn, bSyn-V5,
or aSyn + bSyn-V5 and stained with antibodies against either aSyn or the V5 epitope tag.
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would have to originate from an interaction of aSyn with bSyn.
Using a similar approach, transient interactions between two
aSyn molecules were previously reported (43). In the current
study, we added a 2-fold excess of MTSL-tagged aSyn to the sam-
ple with 15N-labeled bSyn and recorded a {1H–15N}-HSQC experi-
ment. Superposition of the {1H–15N}-HSQC experiments of bSyn
in the absence and presence of aSyn suggested that both the pos-
ition and intensity of the NMR signals of bSyn was unchanged
(Fig. 8A). This was further confirmed by the quantitative analysis
of peak intensities and positions (Fig. 8B): no changes in peak
position were detected. In addition, signal intensities in bSyn,
which were corrected for dilution, were similar in the absence
and presence of aSyn. The small deviations of <0.25 of the I/I0 ra-
tios fromunity ismost likely due to small changes in sample con-
ditions during the titration. In particular, for a specific interaction
between bSyn and aSyn a pronounced (I/I0 ratio < 0.7) broadening
of a distinct region of the bSyn sequence is expected. Taken to-
gether, this analysis shows that monomeric, disordered aSyn
and bSyn have a low propensity to interact in solution, indicating
that additional cofactors are required to trigger their interaction
and aggregation in cells.
Discussion
The heterologous expression of human aSyn in yeast has been
extensively used to obtain important insight into the molecular
basis of PD and other synucleinopathies (35,36,38,44–47).
Despite the obvious similarity among the variousmembers of
the synuclein family, the biological effects of bSyn and gSynwere
only recently assessed in greater detail (8,48). Here, we aimed to
investigate the behavior of human bSyn and gSyn in yeast cells,
upon heterologous expression. We observed that bSyn expres-
sion is also toxic in yeast, similarly to what is observed for aSyn
(33,35). In contrast, expression human gSyn is not toxic, and no
inclusions were formed at the levels of expression used in our
study.
In yeast, expression of aSyn induces the accumulation of
vesicles (45,46,49), raising the question of whether the fluores-
cent foci observed using microscopy are true aggregated forms
of aSyn. However, we recently performed detailed biochemical
characterization of the aSyn species formed in yeast cells and ob-
served that, indeed, they correspond to the formation of highmo-
lecular weight species (36). Moreover, other studies showed that
some of the inclusions formed by aSyn in yeast are thioflavin S or
thioflavin T positive, indicating they have amyloid-like proper-
ties (50,51). Here, we took advantage of FRAP analysis and ob-
served that inclusions formed by bSyn-GFP and aSyn-GFP have
exactly the same dynamics indicating that they share the same
biochemical nature.
We then investigated the mechanisms of toxicity associated
with bSyn expression, asking whether these are similar to
those associated with aSyn expression. Several studies in yeast
revealed that aSyn impairs vesicular trafficking, and that this is
a major component for aSyn-dependent toxicity (40,45,47). We
found that, like aSyn, bSyn toxicity is also associated with ER-
to-Golgi trafficking defects, as the bSyn toxicity could be rescued
by overproduction of genes that increase forward transport be-
tween ER and Golgi (YPT1, YKT6 andUBP3), while the overproduc-
tion of genes that negatively regulate ER-Golgi trafficking (GYP8
and PMR1), exacerbate bSyn toxicity.
Figure 8. NMR characterization of the interaction between disordered aSyn and bSyn in solution. (A) 2D {1H–15N}-HSQC spectrum of {15N}-labeled bSyn in the absence
(green) and presence of a 2-fold excess of aSyn tagged with MTSL at position 90 (red). (B) (Top) The ratio of residue-specific NMR signal intensities observed in
{1H–15N}-HSQC experiments of bSyn in the absence (I0) and presence (I) of MTSL-tagged aSyn. Error bars were calculated on the basis of the signal-to-noise ratio in the
spectra. (Bottom) {1H–15N} chemical shift perturbation in {15N}-labeled bSyn after addition of 2 equivalents of aSyn. Chemical shift perturbations are below the
estimated uncertainty (dashed line) in NMR signal positions. Together with the observation that I0/I ratios are changed by <0.25 (top panel) upon addition of
paramagnetic aSyn shows that monomeric aSyn and monomeric bSyn do not bind strongly to each other in solution.
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The expression of aSyn in yeast cells induces oxidative stress,
which in turn contributes to cell death (37). How aSyn triggers
ROS accumulation is not completely understood, but it has
been proposed that it could be partially an indirect effect, as a
consequence of mitochondrial dysfunction induced by aSyn
(38). Interestingly, we observed that bSyn also increases the levels
of superoxide radical in yeast cells.
The bSyn mutations V70M and P123H have been associated
with rare sporadic and familial cases of DLBs, respectively (14).
Here, we showed that the V70M and P123H mutations increase
bSyn inclusion formation in yeast, in line with the observation
that these mutations induce lysosomal inclusion formation in a
neuroblastoma cell line (15). However, these mutations did not
increase bSyn toxicity. Strikingly, in a transgenic mouse model
expressing P123H bSyn, co-expression of aSyn was found to
greatly enhance neurodegeneration (16). In our yeast model, co-
expression of WT forms of aSyn and bSyn resulted in a severe
growth phenotype, rendering impossible the evaluation of the ef-
fect of the co-expression of the bSyn mutants with aSyn. Never-
theless, our findings are of great significance as the occurrence of
bSyn mutations is rather rare. In addition, our findings suggest
that, increased levels of bSyn may aggravate aSyn-associated
cytotoxicity and neurodegeneration, calling for in depth studies
in synucleinopathy patients, and suggesting gene dosage altera-
tions, due to multiplications or promoter polymorphisms in the
bSyn gene, may play an important and previously unexplored
role in these disorders.
PTMs constitute an essential level of regulation of protein
folding, localization and function. Thus, many PTMs have been
associated with numerous neurodegenerative disorders (29). In
PD and other synucleinopathies, aSyn phosphorylation on S129
is the most studied modification (29). PLK2 and 3 are among the
kinases known to phosphorylate aSyn S129 and were also
found to phosphorylate bSyn on S118 (5). Although there is still
no evidence exist that thismodificationmight have a pathologic-
al role in humans, we found that themutant of bSynwhere phos-
phorylation is mimicked by the introduction of a negatively
charged amino acid (S118D) is more toxic and forms a larger
number of inclusions per cell, suggesting that this modification
might be an important modulator of bSyn toxicity. Future in
vivo studies in animal models will be essential to inform on the
role of this PTM in bSyn in disease. The lack of a specific antibody
that specifically recognizes this phosphorylation unable the
evaluation of the phosphorylation status of bSyn in yeast cells.
However, the results here obtained suggest that, in contrast to
what we previously found for aSyn phosphorylation on S129
(36), S118 of bSyn is not significantly phosphorylated by yeast en-
dogenous kinases, as the behavior of WT bSyn-GFP is more simi-
lar to that of the mutants where phosphorylation is blocked
(S118A or S118G).
We observed that co-expression of aSyn and bSyn is toxic for
yeast cells, and that this toxicity is similar to that observed when
identical levels of aSyn or bSyn are expressed. Interestingly, we
found that co-expression aSyn and bSyn results in an increase
in the percentage of cells with inclusions when compared with
that observedwhen aSyn or bSyn are expressed. In the conditions
tested, based on the use of multicopy vectors, we consider that
our observation is highly important, as it is well established
that increased levels of aSyn, due to genetic or environmental
factors, is a risk factor for PD. In particular, polymorphisms in
the aSyn gene that result in higher levels of expression of the pro-
tein are risk factors for PD (52–54). Our results indicate that in-
creased levels of bSyn may also play an additive effect on aSyn,
similar to what is observed with increased levels of aSyn.
We also asked if aSyn and bSyn could co-aggregate in cells
when both proteins are present. Indeed, we found that aSyn and
bSyn formheterodimers both in yeast andhuman cells. To further
evaluate if co-aggregation was due to a unique propensity of aSyn
and bSyn to interact as monomeric proteins in solution, we per-
formedNMR spectroscopy, because this technique is highly sensi-
tive for even weak protein–protein interactions. While transient
interchain interactions were previously observed between aSyn
molecules (43), we did not observe a direct interaction between
aSyn and bSyn, when the two proteins were in the monomeric,
disordered state. The differences in interchain behavior might
either be caused by differences in solution conditions or be a
consequenceof sequencedifferences between the two synucleins.
Indeed, it is well known that a very high sequence similarity is re-
quired in order for two proteins to assemble together into amyloid
fibrils. Taken together, our data suggest that cellular co-factors are
required to promote co-aggregation of aSyn and bSyn in cells and
thus contribute to synucleinopathies (48).
Previous findings indicated that bSyn could inhibit aSyn ag-
gregation and play a neuroprotective role (11,12,55). However,
more recent reports revealed that bSyn may not always be pro-
tective, in line with the results we now present. In particular,
overexpression of human bSyn using adeno-associated viral
vectors is neurotoxic, and results in the formation of proteinase
K-resistant aggregates of bSyn in primary cultured neurons and
in dopaminergic neurons in rat brain (8). Mutations in bSyn
were linked to DLB and rendered the protein neurotoxic in trans-
genic mice (16). Also, fibrillation of bSyn is promoted by macro-
molecular crowding, metal ions and pesticides (13), all of which
are thought to be associated with PD.
Thus, our findings suggest that, while bSyn might play a pro-
tective role in normal conditions, where it may interact with
aSyn, it might also contribute to disease under pathological con-
ditions that may involve increased levels or toxic environmental
insults. Nevertheless, additional studieswill be necessary to clar-
ify the interplay between aSyn and bSyn in both physiological
and pathological conditions.
Altogether, our study indicates that bSyn can exert cytotox-
icity in a manner that is similar to that caused by aSyn. The
novel yeast models developed herein can be further explored in
powerful genetic screens to further dissect the origin of bSyn tox-
icity, providing additional insight into the molecular basis of
synucleinopathies.
Materials and Methods
Yeast plasmids and strains
aSyn, bSyn gSyn sequenceswere cloned into the SpeI-HindIII sites
of p426GPD, p423GAL or p426GAL yeast expression vectors (34), as
described before (35) (Table 1). GFP fusions were constructed in
the same vectors by inserting the GFP coding sequence as a
ClaI-XhoI digested polymerase chain reaction (PCR) product in
frame with aSyn, bSyn or gSyn (35) (Table 1). Positive constructs
were verified by DNA sequencing. bSyn mutants V70M, P123H,
S118D, S118A and S118G were generated by site directed muta-
genesis of the corresponding plasmids.
Yeast plasmids expressing fusions of aSyn or bSyn to the
N-terminal (VN) or C-terminal (VC) part of Venus (41) (VN-aSyn,
VN-bSyn, aSyn-VC, bSyn-VC) were cloned into the SmaI site of
p423GAL or p426GAL using GENEART Seamless cloning and
assembly kit (Life technologies).
The genes encoding modifiers of aSyn toxicity YPT1, YKT6,
UBP3, GYP8 and PMR1 were cloned as described before (36) in
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pRS-based gateway vectors pAG305GAL (YPT1, YKT6, UBP3, GYP8
and PMR1) (56) (Table 1). These plasmids were integrated in the
W303.1A genome to generate new strains (Table 2).
Yeast transformationswere carriedoutusinga standard lithium
acetate procedure and all the genome insertionswere confirmed by
two independent PCRs following standard procedures (58).
Yeast cultures
Yeast strains were grown in synthetic complete (SC) medium
[6.7 g L−1 yeast nitrogen base (BD Biosciences), appropriate
amino acid dropout mix (Sunrise Science Products) without the
appropriate plasmid selection auxotrophy, uracil (URA) and
leucine (LEU), and with 1% (w/v) raffinose or 1% galactose (w/v)
as carbon source.
For aSyn, bSyn and gSyn expression induction experiments,
yeast cells were pre-grown in SC-URA raffinose liquid media at
30°C, with orbital agitation for 24 h (doubling time: ∼3 h). After
24 h, optical density (OD) at 600 nm (OD600nm) was measured
and yeast cells were diluted to a standardized OD600nm = 3 × 10
−3
(∼2.5 × 105 cells/mL) in SC-URA raffinose liquid media (no repres-
sion of the galactose-inducible promoter) and grown at 30°C,with
orbital agitation. After 24 h, OD600nm was measured. The volume
of yeast culture needed to inoculate a new culture with an initial
standardized OD600nm = 0.4 (∼14 × 106 cells/mL) was centrifuged
(1810 g, at 30°C for 4 min). Cells were then resuspended in SC-
URA galactose liquid media and incubated at 30°C, with orbital
agitation, for 6 h. Co-expression experiments were performed
in the same way, using SC-URA-LEU liquid media with either
raffinose or galactose as carbon source.
For growth assays on solid medium, cultures OD600nm was
normalized to 0.05 ± 0.005 and 1/3 serial dilutions from this
first-cell suspension were prepared. Spots of 4 µl of each cell
suspension were then spotted on plates containing SC-URA or
SC-URA-LEU solid media with glucose (control) or galactose as
carbon source and incubated at 30°C for 3 days.
Protein extraction and immunoblotting analysis
For total protein extraction, yeast cells were lysed in MURB buffer
(50 m sodium phosphate, 25 mMES, pH 7.0, 1% sodium dode-
cyl sulphate (SDS), 3  urea, 0.5% 2-mercaptoethanol, 1 m so-
dium azide) supplemented with protease inhibitor cocktail,
with glass beads (3 cycles of 30 s in the beadbeater and 5 min
on ice). Cell debris was removed by centrifugation (10 000 g,
1 min, room temperature) after denaturation at 70°C and the
supernatant was collected. Equal volumes of total protein, corre-
sponding to the same number of cells (normalized based on
OD600nm)were loaded in the SDS–polyacrylamide gel electrophor-
esis (PAGE) for the detection of aSyn, bSyn or gSyn levels. Protein
samples were heated for 10 min at 70°C and centrifuged at
10 000 g for 1 min before acrylamide gel loading.
After SDS–PAGE run, samples were transferred to a nitrocellu-
lose membrane using a Trans-Blot Turbo transfer system (Bio-
Rad), as specified by the manufacturer.
Immunoblotting was performed following standard proce-
dures using the following antibodies: GFP (NeuroMab); aSyn
(Santa Cruz), bSyn (Abcam) anti phosphoglycerate kinase [PGK
(Life Technologies Corporation)] and GAPDH (Thermo scientific)
was used as loading control.
The band intensity of the different immunoblots signals was
estimated using the ImageJ software (NIH, Bethesda, MD, USA)
and normalized against the corresponding PGK signal. In particu-
lar, aSyn-GFP, bSyn-GFP and gSyn-GFP levels were determined by
calculating the ratio between GFP/PGK and normalized to the
control (mean ± SD).
Fluorescence microscopy and FRAP experiments
The percentage of cells with aSyn-GFP, bSyn-GFP or gSyn-GFP in-
clusions were determined by fluorescence microscopy using a
Zeiss Axiovert 200M (Carl Zeiss) widefield fluorescence micro-
scope equipped with a cooled CCD camera (Roper Scientific Cool-
snap HQ) to acquire images containing at least 400 cells per
strain, which were then manually counted using ImageJ.
Yeast cells were grown as described above. After 6 h of expres-
sion induction in galactose medium cells were collected by cen-
trifugation and resuspended in phosphate-buffered saline (PBS)
and 0.5% low melting agarose on a microscope slide.
FRAP experiments were performed as described before (36),
using a Zeiss LSM 710 inverted laser scanning confocal micro-
scope equipped with a large incubator (Pecon, Erbach, Germany)
maintained at 30°C. Images were acquired using a PlanApochro-
mat 63×/1.4 objective. A series of 80 z-stacks consisting of 5 differ-
ent focal planes spaced 0.7 µm apart (frame size 512 × 512, pixel
width 91 nm and pixel time 4.44 µs) were acquired at intervals of
2 s with pinhole set to 1 Airy unit. In each FRAP experiment a sin-
gle inclusion focused at the central focal plane of the z-stack was
bleached using the 488 nm laser line at 100% laser transmission
on acircular region of interestwith a diameter of 8 pixels (0.35 µm
radius) for 32 ms. For imaging, the transmission of the 488 nm
laser was set to 0.3% of the bleach intensity.
Image processing and fluorescence intensity measurements
were performed in ImageJ using an in-house developed macro
as described before (36).
Flow-cytometry
Flow-cytometry was performed in a fluorescence-activated cell
sorting BD LSRFortessa. Yeast cell membrane integrity was eval-
uatedwith PI staining. Yeast cells were incubatedwith PI 5 µg/mL
for 15 min. As a positive control, cells boiled for 10 minwere used
(data not shown). Fluorescence intensity of aSyn-GFP or bSyn-
GFP was measured in simultaneous using a 488 nm laser for ex-
citation and a 502 LP mirror in conjunction with a 530/30 BP filter
for detection (BD Biosciences, San Jose, CA, USA).
30 µ DHE (Molecular Probe, Life Technologies), for 15 min at
30°C, with agitation and protected from light (59). A minimum of
10 000 events were collected for each experiment. Data analysis
was performed using the FlowJo software (Tree Star, Inc., Ahs-
land, OR, USA). Results were expressed as MFI of a molecule.
Plasmids for mammalian cell culture
Plasmids encoding aSyn fusions with the N-terminal (VN) or
C-terminal (VC) halves of Venus fluorescent protein were previ-
ously described (41,60). To generate the bSyn fusions (VN-bSyn
and bSyn-VC), the aSyn plasmids were cut to remove the aSyn
Table 2. Strains used in this study
Description References
W303-1A MATa; can1-100; his3-11,15; leu2-
3,112; trp1-1; ura3-1; ade2-1
(57)
W303.1A Ypt1 W303.1A pAG305GPD YPT1 LEU2+ This study
W303.1A Ykt6 W303.1A pAG305GPD YKT6 LEU2+ This study
W303.1A Ubp3 W303.1A pAG305GPD UBP3 LEU2+ This study
W303.1A Gyp8 W303.1A pAG305GPD GYP8 LEU2+ This study
W303.1A Pmr1 W303.1A pAG305GPD PMR1 LEU2+ This study
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cDNA, and the cDNA encoding for bSyn was cloned into the NheI
and XhoI sites.
HEK293 cell culture and transfections
HEK293 cells were cultured at 37°C in DMEM medium supple-
mented with 5% FCS, and in a 5% CO2 atmosphere. Cells were
transfected in a 12-well plate, at 80% confluence, with Metafec-
tene (Biontex, Germany) in a ratio of 2:1 with the different synu-
clein-constructs (Fig. 7A and B: VN-aSyn, aSyn-VC, VN-bSyn,
b-Syn-VC; Fig. 7C: aSyn and bSyn-V5), according to the manufac-
turer’s instructions.
Forty-eight hours after transfection, cells were harvested
using radioimmunoprecipitation assay buffer containing 0.1%
Triton X-100, 0.15  NaCl, 50 m Tris, pH 7.5, and a protease
inhibitor cocktail tablet (1 tablet/50 ml) (Roche Diagnostics).
Lysates were centrifuged at 18 400 g for 30 min at 4°C. Protein
concentration was measured using the Bradford assay (Bio-Rad).
SDS–PAGE and western blotting
Forty micrograms of total protein were loaded onto 15% SDS gels
and transferred to nitrocellulose membranes (Immobilon-
FL-Membrane, Millipore, Billerica, MA, USA). Membranes were
washed with Tris-based buffer (TBS), and blocked with 5% Skim
milk in TBS-Tween for 1 h at room temperature. Membranes
were then incubated overnight at 4°C with antibodies against sy-
nuclein (1:2000, Ab6176, pan-synuclein, Abcam, New England,
USA) andwith y-Tubulin (1:3000, Clone GTU-88, Sigma, USA). Fol-
lowing three washing steps with TBS-Tween, membranes were
incubated with horseradish peroxidase-conjugated secondary
antibodies (1:10 000, GE Healthcare) for 2 h at room temperature.
The signal was then detected using Immobilon Western Chemi-
luminescent HRP Substrate (Millipore Corporation).
Immunocytochemistry and microscopy
Forty-eight hours after transfection, cells were washed with PBS
and fixed with 4% paraformaldehyde. Cells were permeabilized
with PBS/0.1% Triton X-100, blocked for 1 h with 1.5% bovine
serum albumin and incubated overnight with the primary anti-
body for aSyn (1:1000, mouse ab610787, BD Transduction Labora-
tories, USA) and for V5 tag (1:1000, rabbit ab9116, Abcam, New
England, USA). After three washes with PBS, the secondary anti-
bodies anti-mouse IgG conjugated to Alexa Fluor 555 (A31570)
and anti-rabbit IgG conjugated to Alexa Fluor 488 (A21206)
(Molecular Probes, OR, USA) 1:1000 was added for 1 h at room
temperature. Cell nuclei were stained with Hoechst dye (Hoechst
33258, Molecular Probes). Fluorescent images were captured
using a Leica Microsystems microscope (Leica DMI 6000B,
Wetzlar, Germany).
Recombinant protein expression and purification
Plasmids encoding aSyn and bSyn were expressed in Escherichia
coli BL21 (DE3) cells. Protein expression and purification was per-
formed as previously described (61). aSyn was conjugated at pos-
ition 90 to the nitroxide tag MTSL following established protocols
(62). The two proteins were then dialyzed against the same NMR
buffer of 50 m 4-(2-hydroxyethyl)-1-piperazineethanesulfonic
acid, 0.02% NaN3, pH 7.4. Experiments were performed on 700
NMR spectrometers (Bruker), equipped with cryogenic probes, at
288 K. NMR experiments were carried out by addition of a 2-fold
excess of unlabeled, MTSL-tagged aSyn to {15N}-labeled bSyn
(100 μ). Before and after addition of aSyn, the pH of the sample
was checked to exclude effects due to pH variation. Heteronuclear
{1H–15N}-HSQC experiments were acquired with 2048(H)*256(N)
complex points (63). Spectra were processed using Topspin (Bru-
ker) and NMRPipe (64) and analyzed with ccpnmr Analysis 2.2.1
(65). For spectral analysis, the backbone assignment of bSyn as de-
posited in the Biological Magnetic Resonance Bank (66) was used.







Statistical analyses were performed using the SigmaStat 3.10
software. All data are reported as averages of three independent
experiments ± standard deviation (SD). Differences between
treatments were detected by one way analyses of variance
(ANOVA) using Tukey honest significant difference multiple
comparison test (α = 0.05).
Supplementary Material
Supplementary Material is available at HMG online.
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